Type 2 diabetes mellitus (T2DM) is a polygenetic disease. Its incidence is increasing continuously in Taiwan as the standard of living improves. Current diabetes research is striving to identify those high at risk of T2DM through T2DM-associated gene studies. A number of techniques are available for the molecular detection of T2DM-associated genes, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), direct sequencing, and TaqMan genotyping. However, they are capable of analyzing only one molecular target in each experiment. In the present study, we selected eight candidate genes that are potentially associated with T2DM [angiotensinogen (AGT), sulfonylurea receptor-1 (SUR-1), peroxisome proliferators-activated receptor-γ (PPAR-γ), PPAR-γ coactivator-1 (PGC-1), calpain-10 (CAPN10), β2-adrenergic receptor (ADRB2), mannose-binding lectin (MBL2), and insulin receptor substrate-1 (IRS-1)]. We used enzymatic chip array technology, which we had previously established, and analyzed its relevance to diabetes research. We enrolled 1280 Taiwanese patients (700 with T2DM and 580 non-diabetic controls). The genes of all subjects were analyzed by the enzymatic chip array. The results were consistent with direct sequencing. On the basis of multivariate logistic-regression analysis-with adjustment for age-the following variables were associated with a significant risk of T2DM: body mass index, serum cholesterol, triglyceride level, low-and high-density lipoprotein cholesterol levels, and polymorphisms, including PGC-1 Gly482Ser, SUR1 Arg1273Arg, ADRB2 Arg16Gly, CAPN10 SNP43, AGT Met235Thr, and MLB2 Gly54Asp. The enzymatic chip array is a useful tool for multiple gene analysis in diabetes.
Introduction
Diabetes mellitus type 2 (T2DM) is a complex multifactorial and polygenetic disorder in which environmental triggers interact with genetic components to lead to disease predisposition.
1 T2DM creates a great deal of human suffering and is a significant financial burden worldwide. One approach to prevent this condition is to identify disease-susceptibility genes. In addition to providing important etiolog ical insights, identifying risk alleles could help clarify which groups of people have a high or low risk of developing T2DM.
Two methods have been used to detect genetic polymorphisms associated with T2DM. One makes use of genome-wide scans-more than 50 such scans have been completed in a variety of ethnic groups. 2 However, these results revealed no single global linkage signal for T2DM. The limitations of genomewide scans are widely accepted for conditions with multifactorial traits. 3 The other method used is T2DM-related genetic polymorphism association studies, which identify several T2DM-associated genes. A number of techniques are available for the molecular detection of T2DM-associated genes, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), direct sequencing, and TaqMan genotyping. 4−6 Applying PCR-RFLP and direct sequencing to detect multiple genes would be time-consuming and laborious in clinical practice. TaqMan genotyping, molecular beacons, and invader assays perform rapid single nucleotide polymorphism (SNP) analysis, 4 but the use of fluorescence as a signal indicator makes these assays very expensive. Although these methods provide useful data, they are limited by only being able to analyze one molecular target in each experiment. Therefore, a robust assay is required, using a high sensitivity and high throughput method that is capable of detecting T2DM genes by using a panel of informative molecular markers simultaneously. In the present study, we used the enzymatic chip array, previously established in our laboratory, 7, 8 as the technological platform for detecting T2DM-associated genes.
By using public databases, including PubMed and Online Mendelian Inheritance in Man, we selected eight candidate genes and nine characterized polymorphisms ( Table 1) that are potentially associated with T2DM [genes selected: angiotensinogen (AGT), sulfonylurea receptor-1 (SUR-1), peroxisome proliferators-activated receptor-γ (PPAR-γ), PPAR-γ coactivator-1 (PGC-1), calpain-10 (CAPN10), β2-adrenergic receptor (ADRB2), mannose-binding lectin (MBL2), and insulin receptor substrate-1 (IRS-1)]. Because of genetic racial/ethnic differences, it is important to construct a database of genes related to T2DM in each racial/ethnic group.
This study explored a high-sensitivity and highthroughput technology to investigate the risk genes related to T2DM in Taiwan. In future research, we hope that these genes can be used in conjunction with preventive medicine in order decrease the incidence of T2DM.
Materials and Methods

Study population
Seven hundred patients with T2DM were included in this study-they were enrolled from Fooyin University Hospital, Pingtung Christian Hospital, and Kaohsiung Medical University Hospital between January 2005 and December 2007. T2DM was diagnosed using the American Diabetes Association (1997) criteria. Non-diabetic controls were recruited from a pool of individuals who had a general health evaluation at the Fooyin University Hospital, Pingtung Christian Hospital, and Kaohsiung Medical University Hospital. The hospital's Human Research Ethics Committee approved the study design, and informed consent was obtained from all participants. T2DM patients received a complete physical examination, as well as an assessment for the presence and extent of macro-or microvascular complications. Routine blood and urine analyses were performed. Measurements were also taken to calculate the body mass index (BMI).
Enzymatic chip array preparation
We used OMP3 to design oligonucleotides of candidate genes. There were four oligonucleotides (two allele specific oligo and two mutant control oligo Sulfonylurea receptor-1 (SUR-1) Arg1273Arg
Peroxisome proliferators-activated Pro12Ala receptor-γ (PPAR-γ) PPAR-γ coactivator-1α (PGC-1) Gly482Ser
Calpain-10 (CAPN10) SNP-43 β2-adrenergic receptor (ADRB2) Arg16Gly Gln27Glu
Mannose-binding lectin (MBL2) Gly54Asp
Insulin receptor substrate-1 (IRS-1) Gly972Arg probes) for each polymorphism ( Table 2 ). The newly synthesized oligonucleotides were dissolved in diwater to a concentration of 20 mM and then placed inside a BioJet Plus 3000 nanoliter dispensing system (BioDot Inc., Irvine, CA, USA), which sequentially blotted the target DNA on a SuPerCharge nylon membrane (Schleicher & Schuell, Dassel, Germany). After being air-dried and UV cross-linked, the membranes were heated at 80°C for 2 hours and stored in a desiccator at room temperature for up to 2 weeks.
Genotyping of polymorphisms
DNA isolation and digoxigenin-labeled DNA
Genomic DNA was extracted from peripheral blood leukocytes using either QIAamp mini kits (Qiagen Inc., Valencia, CA, USA) or Generation Capture Column kits (Gentra Systems Inc., Minneapolis, MN, USA). Polymorphic regions of each gene were amplified by multiple PCRs with two allele-specific sense (or anti-sense) primers (Table 3 ). The reaction mixture contained 20 ng of DNA, 5 pmol of each primer, 2 μL 20 mM of dNTP, 2 μL 30 mM of MgCl 2 , 4 μL of nuclease-free water, and 2 μL1U/μL of polymerase. Next, PCR products were labeled with dTTP: DIG-11-dUTP (Roche Diagnostics, Laval, QC, Canada) as the last step of synthesis. The labeling reaction was carried out at 37°C for 20 hours and then ceased at 70°C for 10 minutes. The mixture of probes was denatured at 90°C for 10 minutes prior to hybridization.
Hybridization and data analysis of colorimetric membrane
The membrane was pre-hybridized and blocked before hybridization. The lifts were incubated with the ExpressHyb Hybridization Solution (BD Biosciences, Palo Alto, CA, USA) containing DIG-labeled SNPspecific library (at 48°C for 12 hours in a humid chamber). After washing, the membrane was incubated with an alkaline phosphatase-conjugated antidigoxigenin antibody (Roche Diagnostics) at 37°C for 1 hour. After removing unbound antibodies by extensive washing, the membrane was incubated in chromogen solution containing nitroblue-tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP) for 15 minutes for color development. The membrane was dried at 60°C, then scanned with an Epson Perfection 1670 flatbed scanner (Seiko Epson Corp., Nagano, Japan). Homozygous and heterozygous SNP genes on the membrane were determined by the development of substrate color.
To confirm the accuracy of genotyping, we randomly selected 50 DNA samples and subjected them to direct DNA sequencing of the PCR products. In each instance, the genotype determined by the membrane assay system was identical to that determined by the confirmatory methods.
Direct sequencing of genes
Sequencing analysis was performed to confirm the following genes by membrane assay: AGT Met235Thr, PGC-1 Gly482Ser, SUR1 Arg1273Arg, CAPN10 SNP43, IRS1 Gly972Arg, PPARγ Pro12Ala, MBL2 Gly54Asp, ADRB2 Arg16Gly, and Gln27Glu. The PCR amplification of DNA samples was performed within a 50 μL vessel containing 34 μL of H 2 O, 2 μL of genomic DNA, 5 μL of 10X PCR buffer, 5 μL of dNTP mixture (2.5 mM), 2 μL of primers mixture (20 μM), and 2 μL of Taq polymerase (5 U). Reactions were conducted in a programmable thermal cycler (PTC-100; MJ Research, Watertown, MA, USA) under the following conditions: 30 denaturing cycles for 30 seconds at 95°C, annealing for 6 seconds at 71°C, and extension for 30 seconds at 72°C. The PCR products were purified by the QIAEX II Gel Extraction Kit (Qiagen Inc.) and then subjected to sequencing. The sequences were analyzed by Protech Technology Enterprise Co. Ltd. (Taipei, Taiwan). 
Biochemical analyses
We measured total cholesterol (TC) and triglyceride (TG) levels with a biochemical analyzer (SYNCHRON CX-5CE; Beckman Coulter Inc., Fullerton, CA, USA). The TC and TG levels were analyzed using the CHOD-POD method and the Lipase-GOD-POD method (Beckman Reagent Kit; Beckman Coulter Inc.), respectively. The high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) fractions were measured using an electrophoresis analyzer (Helena REP; Helena Laboratories, Beaumont, TX, USA).
Statistical analysis
The clinical and biochemical features of the population are presented as mean ± standard deviation. Odds ratios and 95% confidence intervals were determined to assess the genetic differences between the two groups. The observed frequencies of the genes were compared using the Hardy-Weinberg equilibrium by χ 2 tests. 9 Student's t tests were used to detect mean differences in biochemical data. All p values were calculated based on two-sided tests with statistical significance defined as p < 0.05. Table 4 lists the characteristics of controls and T2DM patients. Age distribution was not significantly different between the two groups. According to random selection criterion, as was expected, the diabetic patients had higher BMI, higher systolic blood pressure, higher serum cholesterol, and higher TG and LDL-C levels compared with controls. In addition, the serum HDL-C level was significantly lower in T2DM patients. Figure 1 shows the reaction doctrine of the oligoenzymatic chip array. On the established enzymatic chip array, each oligo probe encodes in double repetition. A mutant control oligonucleotide (MCO) was designed for each allele-specific oligonucleotide (ASO). There was only one nucleotide difference between the MCO and the ASO. A DNA fragment that can be hybridized with allele-specific oligo probes, but not with mutant control oligo probes, is considered true positive, and a positive hybridization turns blue−purple after color fixatives are added. Therefore, after comparison with the C allele results, one test was identified as a TT genotype sample (Figure 1) .
Results
The enzymatic chip array was confirmed with direct sequencing by randomly selecting 50 DNA samples and subjects. The accuracy of genotyping by the enzymatic chip array method was consistent with the results of direct sequencing (Figure 2 ). Figure 2A shows the genes of one subject by direct sequencing [PGC1 Gly482Ser (AG), SUR1 Arg1273Arg (GG), AGT Met235Thr (CC), ADRB2 Arg16Gly (GA), and CAPN10 SNP43 (GG)]. The same DNA sample was applied to the enzymatic chip array system, which revealed results identical to those of direct sequencing. Figure 3 shows the genes of another subject [PGC1 Gly482Ser (AG), SUR1 Arg1273Arg (GG), AGT Met235Thr (CT), ADRB2 Arg16Gly (AA), ADRB2 Gln27Glu (CC), IRS1 Gly972Arg (AG), PPAR-γ Pro12Ala (CC), MBL2 Gly54Asp (AG), and CAPN10 SNP43 (GG)]. Identification was based on the membrane substrate color (blue−purple). The membrane assay method was performed with simple devices and materials according to standard procedures.
On the basis of multivariate logistic-regression analysis-with adjustment for age-the following variables were associated with a significant risk of T2DM: BMI, serum cholesterol, TG, LDL-C/HDL-C levels, and polymorphisms, including PGC-1 Gly482Ser, SUR1 Arg1273Arg, ADRB2 Arg16Gly, CAPN10 SNP43, AGT Met235Thr, and MLB2 Gly54Asp (Table 5 ). All genotypic distributions were examined assuming the Hardy-Weinberg equilibrium.
Discussion
Molecular detection of T2DM genes by PCR-RFLP and direct sequencing has been used increasingly in the last decade. However, applying PCR-RFLP and direct sequencing for the detection of multiple genes would be too time-consuming for clinical practice. In the present study, we used an enzymatic chip array method, which not only accurately detected multiple genetic polymorphisms simultaneously, but also used a simple set of devices and materials, and used simple procedures. Both the difficulty and cost of the experiment were relatively minimal. Therefore, this technique has merit and should be considered for A B
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Figure 3
Genes of one subject identified based on the substrate color (blue−purple) from the enzymatic chip array.
detecting polymorphisms of candidate genes associated with polygenetic diseases including T2DM. T2DM is a polygenetic disease. Thus, simultaneous detection of multiple genetic polymorphisms is required. Racial and ethnic differences in genetic polymorphisms exist, and it is vital to construct a database of T2DM-associated genes for each racial and ethnic group. In this study, we examined nine polymorphisms in nine candidate genes in 1,006 Taiwanese patients and controls. The results revealed that certain polymorphisms were associated with a significant risk of T2DM in Taiwanese people (PGC-1 Gly482Ser, SUR1 Arg1273Arg, ADRB2 Arg16Gly, CAPN10 SNP43, AGT Met235Thr, and MLB2 Gly54Asp).
A meta-analysis showed that the PGC-1 Gly482Ser polymorphism is associated with T2DM in a Caucasian population. 10 Other studies 11, 12 have revealed that PGC-1 Gly482Ser polymorphisms are not associated with T2DM. Recently, this polymorphism was reported to be a predictor for the conversion from impaired glucose tolerance to T2DM. 13 Our results suggest that the AA genotype PGC-1 Gly482Ser polymorphism is a risk factor for T2DM in the Taiwanese population.
The AGT Met235Thr gene polymorphism was reported to not be associated with diabetes in 400 Taiwanese persons (including diabetes patients).
14 AGT plays a role in regulating the growth and differentiation of adipose tissue, 15 and AGT synthesis in the liver is regulated by insulin, so it is likely that AGT may affect insulin resistance. 16, 17 Guo et al 18 found that the Thr allele of AGT M235T was significantly associated with increased insulin resistance in Mexican Americans. Takakura et al 19 reported that the CC genotype of AGT Met235Thr gene polymorphism was linked to visceral obesity and insulin resistance in Japanese women. The results of our analyses suggest that the CC genotype is a risk factor for T2DM. ADRB2 Arg16Gly and Gln27Glu gene polymorphisms are associated with T2DM. 20−22 One study of a Taiwanese population 23 revealed that ADRB2
Arg16Gly, but not Gln27Glu, was associated with T2DM. Our results suggest that the Arg genotype of the ADRB2 Arg16Gly gene is a risk factor for T2DM, a view consistent with the latter observation. The MLB2 Gly54Asp gene polymorphism was associated with gestational diabetes mellitus in a population from Spain. 24 MBL is a plasma protein synthesized in the liver and released as a component of the acute-phase response. 25 MBL may aggravate local and systemic inflammation through complement activation 26, 27 and modulation of proinflammatory cytokine production. 28 Inverse correlations between indexes of insulin sensitivity and serum markers of inflammation have been found. 29, 30 Our results suggest that the MLB2 Gly54Asp gene polymorphism is a risk factor for T2DM.
The CAPN10 gene is the first T2DM candidate gene identified through genome-wide linkage and positional cloning. 31 Horikawa et al first reported that G allele homozygosity in UCSNP-43 was associated with T2DM. One meta-analysis 32 confirmed that individuals who are homozygous for the G allele had a 19% increased risk of T2DM. Our results suggest that homozygosity of the G allele in UCSNP-43 of CAPN10 gene polymorphism is a risk factor for T2DM.
The SUR1 Arg1273Arg polymorphism was associated with high insulin concentrations in normal individuals from an ethnic group with a high risk for diabetes. 33 Reis et al 34 showed that this polymorphism is associated with T2DM in French Caucasians. Recently, the SUR1 Arg1273Arg polymorphism was shown to be associated with T2DM in Finnish subjects. 35 Our study suggests that AA and AG genes are risk factors for T2DM.
T2DM involves the interplay of several candidate genes. The enzymatic chip array method used here was designed to quickly screen a large number of genes with preselected polymorphisms, based on the current literature. This method limits the numbers of polymorphisms in each gene and may decrease the ability to detect their effects, even if they are important. However, the polymorphisms tested in this study were those specifically identified in previous reports. A possible limitation of this study is that a spurious association may arise from selection bias, population stratification, multiple hypothesis testing, subgroup analysis, and inadequate statistical power. In our study, 1006 subjects were recruited and statistical significance was found. Therefore, the statistical power was adequate. We characterized these polymorphisms in a homogeneous ethnic population from a restricted geographical area that had no recent immigration.
In conclusion, this study outlined the creation of the enzymatic chip array-a method performed with simple devices and materials with a straightforward procedure. It was designed to simultaneously detect multiple genetic polymorphisms of T2DM-associated genes. Determination of these genes (outlined above) may be useful in predicting the genetic risk of T2DM in the Taiwanese and other populations. Further research is required to elucidate the possible genetic mechanisms in T2DM, and to develop the application of our method to clinical practice.
